Answers are grounded in this paper and cite their sources.
We report clinical outcomes of patients with localized and advanced spindle cell/sclerosing rhabdomyosarcoma (S-RMS) from the Pushing Ultra-Rare Sarcomas Towards Hope (PUSH) consortium, an international collaborative network. Clinical data from patients with molecularly confirmed S-RMS treated at 25 institutions between January 2013 and December 2023 were reviewed. Endpoints included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and overall response rate (ORR). Univariate analyses were performed. Sixty-four patients were identified. The most common molecular alteration was MYOD1 p.L122R mutation (56%). Among patients with localized S-RMS (n=42), the 3-year OS and DFS rates were 61.2% and 34.2%, respectively. Local recurrence was more frequent than distant metastasis (14 vs. 8). Tumor size was significantly associated with DFS (P=0.008) and distant metastasis (P=0.012). Among patients with advanced S-RMS (n=37), median OS was 14.8 months (95% CI: 10.1-28.0), with 26.2% alive at 2 years. Lung metastasis was associated with worse OS (HR=4.07, P=0.004). Twenty-nine patients (78%) received first-line chemotherapy, most commonly anthracycline-based treatment (48%). The median PFS was 5.4 months (95% CI: 3.7-12.0), and evaluable ORR was 24% (6/25). The evaluable ORR was 27% in MYOD1-altered and 22% in TFCP2-altered patients across all treatment lines. These findings suggest that ∼one-third of patients with completely resected localized S-RMS may be cured. The predominance of local recurrence highlights the need to optimize locoregional management. Advanced S-RMS has a poor prognosis, and conventional systemic therapies provide limited benefit, underscoring the urgent need for novel treatments.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: